Perspectum

What Perspectum does

Perspectum is a UK-headquartered medical technology company founded in 2012 in Oxford that develops AI-powered quantitative MRI imaging software for non-invasive diagnosis and monitoring of liver and multi-organ disease. Its core technology platform processes standard MRI scans through proprietary algorithms to extract biomarkers including corrected T1 (cT1), proton density fat fraction (IDEAL-PDFF), and T2* iron measurements, eliminating the need for invasive liver biopsies or contrast agents. The product portfolio includes the FDA-cleared and CE-marked LiverMultiScan for liver assessment, CoverScan for multi-organ imaging (including MHRA-approved CoverScan MD for Long COVID), MRCP+ for biliary disease (first FDA-cleared quantitative AI tool in this category), Hepatica for surgical decision support in liver cancer care, Atlas for cardiometabolic clinical trials, and VitruvianScan for body composition analysis, with a Perspectum Portal cloud platform for results management.

The company operates four primary revenue streams: clinical diagnostic services (per-scan fees for LiverMultiScan reports processed through a secure reporting laboratory), pharma imaging CRO services (quantitative MRI endpoints and site network management for 30+ NASH and other clinical trials), technology licensing to clinical partners and distributors, and software subscriptions via Perspectum Portal. Customers include pharmaceutical sponsors running clinical trials in NASH/MASLD, oncology, and cardiometabolic disease, healthcare providers such as Massachusetts General Hospital and UVA Health, research institutions including UK Biobank (60,000+ participants), and patient populations served through the Oxford Community Diagnostic Centre (60,000+ patients in 2024, scaling to 100,000+ by 2027).

Perspectum has raised approximately $140M in total venture funding, including a $55M Series C led by Oppenheimer Holdings in 2023. The company operates from Oxford (headquarters), Dallas, San Francisco, Cambridge MA, Lisbon, and Singapore, with products available in 28 countries across a 300+ site imaging network. As of January 2026, the company is undergoing a leadership transition following the departure of founder-CEO Dr. Rajarshi Banerjee, with COO Dr. Rexford Newbould serving as Interim CEO and former Merck CMO Dr. Mike Rosenblatt as Executive Chair.

Name

Perspectum

Legal name

Perspectum Ltd

Website

https://perspectum.com

Company type

Private

Founded year

2012

Operating status

Operating

Headcount range

251–500 employees

Short description

Perspectum is an Oxford-based medical technology company that develops FDA-cleared AI-powered quantitative MRI imaging software (LiverMultiScan, CoverScan, MRCP+) to non-invasively diagnose and monitor liver and multi-organ disease for pharmaceutical sponsors, healthcare providers, and research institutions across 28 countries.

Ownership category

akta.pro rank

Product category

Medical Imaging Software

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Medical Laboratories (621511)

SIC

Surgical & Medical Instruments & Apparatus (3841), Services-Medical Laboratories (8071)

akta.pro industry

PRIMARYHLAHABAC

Magnetic Resonance Imaging (MRI) Systems

Healthcare & Life Sciences/Medical Devices & Diagnostics/Medical Imaging & Radiology Equipment

SECONDARYHLACALAC

Vendor Neutral Archive (VNA) & Enterprise Imaging Repositories

Healthcare & Life Sciences/Digital Health & Health IT/Medical Imaging Informatics (PACS/RIS/VNA) & Radiology IT

SECONDARYHLALAFAA

Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity)

Healthcare & Life Sciences/Telehealth Platforms/Chronic Care & Remote Patient Monitoring (RPM) Platforms

SECONDARYHLAKABAE

Non-Invasive Cardiac Imaging (Echo/CT/MRI/Nuclear)

Healthcare & Life Sciences/Specialist Medical Practice/Cardiology & Vascular Medicine

Keywords

• Quantitative MRI imaging
• Liver disease diagnostics
• Imaging biomarkers
• Medical imaging software
• Clinical trial imaging

Headquarters

HQ city

Oxford

HQ country

United Kingdom

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Clinical Diagnostic Services: Perspectum provides LiverMultiScan diagnostic reports to healthcare providers and imaging centers. Scans are sent electronically to Perspectum's secure reporting laboratory, quantified using proprietary algorithms, with results returned to referring doctors typically within 24 hours. Revenue is generated per scan/service delivered to clinical customers.
2. Pharma Imaging CRO Services: Perspectum acts as an imaging CRO providing quantitative MRI biomarkers for pharmaceutical clinical trials in NASH, MASLD, oncology, and cardiometabolic disease. They provide imaging endpoints, site network management, and data analysis services. Sponsors pay per study or per patient imaging assessment.
3. Technology Licensing: Perspectum licenses its technology and trademarks to clinical partners, imaging centers, and distributors. Partners receive access to use LiverMultiScan and related trademarks under license agreements for a fee.
4. Research Platform / Software Subscriptions: Perspectum Portal provides researchers and clinicians access to imaging data, analytics, and reporting tools. Subscription-based access to software platform for managing and interpreting imaging results.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels7 records

Core offering

Perspectum develops and commercializes AI-powered quantitative MRI imaging software medical devices that extract proprietary biomarkers (cT1, PDFF, iron) from standard MRI scans for non-invasive diagnosis and monitoring of liver and multi-organ diseases. Its flagship FDA 510(k)-cleared and CE-marked product, LiverMultiScan, serves both clinical healthcare providers (per-scan diagnostic services) and pharmaceutical sponsors (imaging CRO services for clinical trials in NASH, MASLD, oncology, and cardiometabolic disease).

Product overview

Perspectum is a medical technology company offering a portfolio of AI-powered quantitative MRI imaging products. The core offering includes LiverMultiScan (FDA-cleared liver assessment), CoverScan (multi-organ imaging), MRCP+ (biliary imaging), Hepatica (surgical planning), and VitruvianScan (body composition). These products share a common technology platform that extracts proprietary biomarkers (cT1, PDFF, iron) from MRI scans using AI algorithms. Atlas provides pharma sponsors with multi-organ imaging capabilities for clinical trials. The company also operates Perspectum Portal as a cloud-based results management platform. Products are available for both clinical practice and clinical trial use, with global operations spanning the UK, US, and Asia.

Differentiator

Problem solved

Functional benefit

Brands

• LiverMultiScan: FDA-cleared non-invasive MRI technology for liver disease diagnosis, monitoring, and clinical management
• CoverScan
• MRCP+
• Hepatica
• Atlas
• cT1
• VitruvianScan

Products and services

• LiverMultiScan FDA 510(k)-cleared and CE-marked non-invasive MRI software medical device that assesses liver disease activity, fat, and iron using existing MRI infrastructure. Extracts proprietary biomarkers including corrected T1 (cT1) and proton density fat fraction (PDFF) for diagnosis, monitoring, and clinical management of patients with liver diseases. Results are typically returned within 24 hours.
• CoverScan Multi-organ MRI technology that assesses multiple organ systems including liver, heart, and kidneys using proprietary biomarkers. Used for metabolic disease assessment, Long COVID research (CoverScan MD), and multi-organ health evaluation. Nominated for Prix Galien USA 2024 Best Digital Health Solution award.
• MRCP+ FDA-cleared quantitative imaging tool for biliary disease that provides AI-powered assessment of the bile ducts. The first quantitative AI tool for biliary disease cleared by the FDA, enabling objective evaluation of hepatobiliary diseases including primary sclerosing cholangitis (PSC).
• Hepatica Non-invasive MRI technology that informs surgeons about previously undiagnosed background liver disease, helping improve surgical decision-making in liver cancer care by assessing liver tissue health prior to surgery.
• Atlas Multi-organ imaging offering for pharmaceutical sponsors providing AI-powered whole-image analysis and a metabolic software suite with measures of multi-organ health including cardiac imaging (quantitative cardiac volume, strain imaging, aortic stiffness). Supports cardiometabolic disease clinical trials.
• Perspectum Portal Cloud-based portal providing researchers and clinicians access to imaging data, analytics, and reporting tools. Enables users to view, share, and track patient imaging data and reports, with subscription-based access for managing and interpreting imaging results.
• VitruvianScan Body composition analysis tool referenced in Perspectum product manuals, enabling quantitative assessment of body tissue composition using MRI technology.

Quantifiable outcome

• cT1 resulted in lowest per-patient costs for resmetirom treatment pathway: $7,022 vs $7,268 for biopsy vs $28,509 for VCTE in VA healthcare enrollees
• +6 more outcomes

Named customers11 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability5 records

Feature8 records

Partnerships

14 partnerships are on record, tiered major, core and minor.

• MASHNET (MASLD Diagnostic Coalition)majorStrategic or Co-development Partner · 3 February 2026Perspectum is a founding member of the MASLD Diagnostic Coalition formed by MASHNET to improve access and awareness of non-invasive diagnostics for MASLD. Coalition founding members include Echosens, E-Scopics, Labcorp, Siemens Healthineers, and Sonic Incytes, supported by Novo Nordisk. Coalition aims to advance early detection, public education, and collaborative efforts to address underdiagnosis.
• Avant SantémajorStrategic or Co-development Partner · 17 December 2025Strategic partnership to support clinical research programs across metabolic health and liver disease in Mexico and Latin America. Perspectum's quantitative MRI biomarkers will be integrated into Avant Santé's research ecosystem, enabling standardized, non-invasive imaging endpoints in clinical trials. Joint approach designed to reduce study start-up timelines and accelerate implementation of imaging endpoints.
• InHealth GroupcoreStrategic or Co-development Partner · 2 December 2025National diagnostics partnership to significantly expand access to advanced MRI and increase capacity at the Oxford Community Diagnostic Centre. Perspectum and InHealth will introduce advanced MRI capabilities across InHealth's national network of 850+ locations. The partnership also includes creation of a joint research network to deliver multi-centre studies including the UK Imaging Diabetes Study (UKIDS) at greater scale.
• GE HealthcaremajorStrategic or Co-development PartnerCollaborated with GE Healthcare as part of the ID-LIVER project (£4.4M Innovate UK/Cancer Research UK funded) to integrate LiverMultiScan into Roche/GE NAVIFY clinical decision support platform. Also part of broader consortium for AI solutions in liver disease diagnostics with Manchester and Nottingham Universities, Roche Diagnostics, and Jiva.AI.
• Roche DiagnosticsmajorStrategic or Co-development PartnerCollaboration through ID-LIVER project to integrate LiverMultiScan quantitative MRI technology into Roche/GE NAVIFY clinical decision support platform, displaying diagnostic and patient data in a single holistic view for liver disease assessment.
• University of ManchesterminorStrategic or Co-development PartnerResearch partner in the ID-LIVER project (£4.4M funding) focused on AI solutions for liver disease diagnostics and liver cancer prevention. Led by Professor Neil Hanley with Manchester University NHS Foundation Trust.
• University of NottinghamminorStrategic or Co-development PartnerResearch partner in the ID-LIVER project focused on AI solutions for early liver disease diagnostics.
• UK BiobankcoreStrategic or Co-development PartnerCollaborative research partner using LiverMultiScan technology for UK Biobank's landmark imaging study (60,000+ participants). Perspectum technology has been used to analyze liver health data across UK Biobank participants, identifying NASH prevalence and genetic markers associated with fatty liver disease and iron overload.
• UT Southwestern Medical CenterminorStrategic or Co-development PartnerCollaboration to include LiverMultiScan technology in the Dallas Heart & Minds Study (DHMS) to measure chronic liver disease and understand interactions between genetics, environment, and lifestyle on liver health.
• Marubeni CorporationminorChannel Partner/ Reseller/ DistributorStrategic business partnership to bring LiverMultiScan to Japan. Marubeni (through Clairvo subsidiary) supports market entry and distribution of Perspectum's imaging technology in Japan.
• ProPathminorStrategic or Co-development PartnerPartnership combining imaging and pathology services for pharmaceutical companies running clinical trials in liver disease (NAFLD/NASH). Provides streamlined clinical data management through a single cloud-based platform integrating data from both imaging and pathology modalities.
• 3T Radiology & ResearchminorChannel Partner/ Reseller/ DistributorPartnership to deliver advanced liver diagnostics to patients in the US, addressing one of the most common undiagnosed pre-existing health conditions using LiverMultiScan.
• National Cancer Centre SingaporeminorStrategic or Co-development PartnerCollaboration on landmark study for early detection of liver cancer using precision medicine, in partnership with NCCS and other collaborators.
• Massachusetts General HospitalminorStrategic or Co-development PartnerFDA grant awarded to Perspectum and physicians at MGH to accelerate development of imaging biomarkers as drug development tools in liver disease.

Scale indicators8 records

Recent moves6 records

Expansion highlights7 records

Direct peers

• Echosens: Echosens manufactures FibroScan, the leading point-of-care non-invasive liver diagnostics device using transient elastography. Direct competitor in liver disease assessment with broader primary care deployment and lower per-scan cost; co-founding member of MASHNET coalition alongside Perspectum.
• Resonance Health: Resonance Health provides FerriScan and HepaFat-Scan, FDA-cleared MRI-based liver iron and fat quantification biomarkers for clinical and research use. Closest direct competitor in quantitative MRI liver biomarkers, serving overlapping pharma CRO and clinical segments.
• Clario (formerly Bioclinica): Clario is a global imaging CRO providing medical imaging endpoint services and centralized image analysis for pharmaceutical clinical trials. Direct competitor in the pharma imaging CRO segment where Perspectum serves 30+ NASH trials.

Broad incumbents

• Siemens Healthineers: Siemens Healthineers manufactures MRI systems and broader medical imaging equipment with AI-enabled post-processing software. Broad incumbent in medical imaging infrastructure; member of MASHNET coalition; potential both as partner (OEM channel) and competitor (in-house quantitative imaging).
• GE Healthcare: GE Healthcare manufactures MRI scanners and operates the NAVIFY clinical decision support platform (jointly with Roche), into which Perspectum's LiverMultiScan integrates via the ID-LIVER project. Established imaging incumbent with overlapping enterprise imaging informatics capabilities.
• Philips Healthcare: Philips Healthcare is a major medical imaging equipment manufacturer with MRI systems and enterprise imaging informatics suites. Broad incumbent competitor in MRI hardware and integrated imaging software for clinical and research workflows.
• ICON plc: ICON plc is a large global CRO offering full-service and functional service clinical trial solutions including central imaging and biospecimen services. Broad incumbent offering imaging CRO services that compete for NASH and metabolic disease trial sponsors.
• Labcorp: Labcorp is a global clinical laboratory and diagnostics services provider with extensive liver and metabolic disease testing capabilities. Founding member of the MASHNET MASLD Diagnostic Coalition alongside Perspectum; competes in NASH/MASLD diagnostics and clinical trial central lab services.

Emerging players

• HepQuant: HepQuant develops dual-clearance blood-based tests for liver function assessment. Strategic partner with Perspectum (combining imaging and functional assessment) but also a partial competitor in non-invasive liver disease assessment for clinical trials and chronic liver disease management.
• Paige: Paige is an AI digital pathology company focused on cancer diagnostics, with a strategic partnership combining its pathology capabilities with Perspectum's MRI imaging for late-stage clinical trials. Comparable AI-in-medical-imaging business model targeting pharma sponsors.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/perspectum-ltd
• Xx.com/PerspectumGroup
• Facebookfacebook.com/perspectum

Compliance6 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles14 records

Subsidiaries4 records

Funding overview

Funding rounds10 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Perspectum